This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gan, V N Articles by Nelson, J D Search for Related Content PubMed PubMed Citation Articles by Gan, V N Articles by Nelson, J D

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 May; 35(5): 967-971

Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.

V N Gan, H Kusmiesz, S Shelton and J D Nelson

Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas 75235-9063.

ABSTRACT

One hundred five infants and children with acute otitis media were randomized to therapy with loracarbef, an experimental carbacephem antibiotic, or amoxicillin-clavulanate (Augmentin), an approved drug for this disease. Ninety-two were evaluable (46 in each group). Middle ear fluid samples obtained for culture before therapy grew Haemophilus spp. in 30% of cases, pneumococci in 29% of cases, and Moraxella catarrhalis in 15% of cases. beta-Lactamase-producing bacteria were found in 37% of patients. Clinical failure occurred in four loracarbef-treated patients and one amoxicillin-clavulanate-treated patient (P = 0.361). Recurrence of acute otitis media was more common in the 2 to 3 weeks after loracarbef treatment (eight patients) than it was after amoxicillin-clavulanate therapy (three patients), but not significantly so (P = 0.197). Thus, combined failure and recurrence occurred in 12 loracarbef-treated patients and four amoxicillin-clavulanate-treated patients (P = 0.052). Gastrointestinal side effects occurred in 13 loracarbef-treated and 21 amoxicillin-clavulanate-treated patients (P = 0.13). Diaper rash was more common with amoxicillin-clavulanate (22 patients) than with loracarbef (10 patients; P = 0.016). Satisfactory results were achieved with both antibiotics, and adverse effects, although common, were minor.

---

Antimicrob Agents Chemother. 1991 May; 35(5): 967-971

This article has been cited by other articles:

• Greiner, O., Day, P. J. R., Altwegg, M., Nadal, D. (2003). Quantitative Detection of Moraxella catarrhalis in Nasopharyngeal Secretions by Real-Time PCR. J. Clin. Microbiol. 41: 1386-1390 [Abstract] [Full Text]  
• Zaleski, A., Scheffler, N. K., Densen, P., Lee, F. K. N., Campagnari, A. A., Gibson, B. W., Apicella, M. A. (2000). Lipooligosaccharide Pk (Galalpha 1-4Galbeta 1-4Glc) Epitope of Moraxella catarrhalis Is a Factor in Resistance to Bactericidal Activity Mediated by Normal Human Serum. Infect. Immun. 68: 5261-5268 [Abstract] [Full Text]  
• Aebi, C., Cope, L. D., Latimer, J. L., Thomas, S. E., Slaughter, C. A., McCracken, G. H. Jr., Hansen, E. J. (1998). Mapping of a Protective Epitope of the CopB Outer Membrane Protein of Moraxella catarrhalis. Infect. Immun. 66: 540-548 [Abstract] [Full Text]